NYSE:PBHPrestige Consumer Healthcare Stock Price, Forecast & News

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PBH stock has increased by 13.1% and is now trading at $40.61. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Prestige Consumer Healthcare.

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Prestige Consumer Healthcare.

Prestige Consumer Healthcare Inc (NYSE:PBH) issued its quarterly earnings results on Thursday, May, 7th. The company reported $0.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.74 by $0.08. The business had revenue of $251.20 million for the quarter, compared to analyst estimates of $239.65 million. Prestige Consumer Healthcare had a return on equity of 13.33% and a net margin of 14.77%. The firm's revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.72 EPS. View Prestige Consumer Healthcare's earnings history.

Prestige Consumer Healthcare issued an update on its first quarter earnings guidance on Thursday, May, 7th. The company provided EPS guidance of $0.70 or more for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.69. The company issued revenue guidance of ~$220 million or more, compared to the consensus revenue estimate of $232.21 million.

7 analysts have issued 1 year price objectives for Prestige Consumer Healthcare's shares. Their forecasts range from $43.00 to $91.00. On average, they expect Prestige Consumer Healthcare's stock price to reach $71.00 in the next year. This suggests a possible upside of 74.8% from the stock's current price. View analysts' price targets for Prestige Consumer Healthcare.

Media coverage about PBH stock has trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Prestige Consumer Healthcare earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days. View the latest news aboutPrestige Consumer Healthcare.

Some companies that are related to Prestige Consumer Healthcare include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), USANA Health Sciences (USNA), Inter Parfums (IPAR), Medifast (MED), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Gilead Sciences (GILD), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), Johnson & Johnson (JNJ), TG Therapeutics (TGTX), Flexion Therapeutics (FLXN), Marathon Petroleum (MPC), Pfizer (PFE), AT&T (T) and Thermo Fisher Scientific (TMO).

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.66%), Champlain Investment Partners LLC (4.92%), Wells Fargo & Company MN (4.01%), JPMorgan Chase & Co. (3.82%), State Street Corp (3.55%) and Acadian Asset Management LLC (2.99%). Company insiders that own Prestige Consumer Healthcare stock include Paton Brett, Ronald M Lombardi and Timothy Connors. View institutional ownership trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., BlackRock Inc., JPMorgan Chase & Co., First Manhattan Co., Invesco Ltd., Massachusetts Financial Services Co. MA, The Manufacturers Life Insurance Company , and Morgan Stanley. View insider buying and selling activity for Prestige Consumer Healthcare.

PBH stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, AQR Capital Management LLC, Grantham Mayo Van Otterloo & Co. LLC, Monarch Partners Asset Management LLC, Champlain Investment Partners LLC, Jennison Associates LLC, Acadian Asset Management LLC, and Citigroup Inc.. View insider buying and selling activity for Prestige Consumer Healthcare.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $40.61.

Prestige Consumer Healthcare has a market capitalization of $2.03 billion and generates $963.01 million in revenue each year. The company earns $142.28 million in net income (profit) each year or $2.96 on an earnings per share basis. Prestige Consumer Healthcare employs 530 workers across the globe.

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]